My greater enthusiasm resides with the future fortunes of my home Region of Northwest Indiana, and we're faced with a ...
The 1968 AMC AMX stands as one of the most audacious gambles in automotive history. While the “Big Three” (Ford, GM, and ...
Strengthening the clinical leadership as the Company progresses to the clinic with its BRD9 Targeted Glue™, AMX-883, in acute ...
Confusingly, the ad for today's Nice Price or No Dice AMX describes its condition as "excellent" despite the car lacking much of its interior trim, and, on the outside, some of its paint. Let's decide ...
Hosted on MSN
The AMX-10 RC’s fearsome return to combat
The AMX-10 RC’s fearsome return to combat Posted: February 9, 2026 | Last updated: February 9, 2026 This French armored vehicle is back on the battlefield with a lethal reputation. From dominating ...
Nigel first entered the world of automotive journalism in the mid-80s, working for what was then the “bible” of weekly automotive content - Motoring News. Those were the days of tip-tap typewriters, ...
America Movil remains undervalued, with over 20% upside, but lacks a clear investor base due to modest growth and payouts. Lower capex spending, market consolidation in Colombia and the Southern Cone, ...
Matt Nelson is an automotive journalist with nearly a decade of experience in all things cars. He's spent years working at dealerships in sales, finance, and service. He's since traded in his pens and ...
ALEXANDRIA, Va., January 22, 2026--(BUSINESS WIRE)--Oxford Finance LLC ("Oxford"), a leading specialty finance firm, is proud to announce the successful closing of its first transaction under its ...
CAMBRIDGE, Mass.-- (BUSINESS WIRE)--Jan 8, 2026-- CAMBRIDGE, Mass.-- (BUSINESS WIRE)--Jan 8, 2026-- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the ...
A downtrend has been apparent in Amer Movil (AMX) lately with too much selling pressure. The stock has declined 10.9% over the past four weeks. However, given the fact that it is now in oversold ...
Amphista Therapeutics has reported preclinical leukemia data on its protein degrader, positioning the Big Pharma-partnered biotech to target a 2026 start date for a phase 1 clinical trial. The data, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results